Ababax Health

Overview

Ababax Health is a digital health technology company dedicated to developing Digital Drugs that enable tailored, non-invasive digital interventions to unlock and advance mental and physical health. By uniting multidisciplinary scientists and technology experts, Ababax aims to shape the future of medicine through innovative solutions. The founders, Dr. Markus Müschenich and Christian Lautner, have been Founding Investors at Dopavision since 2017. Ababax Health focuses on creating Software-as-a-Drug competencies by pooling expertise from various fields to develop digital interventions that address both mental and physical health challenges. Their approach emphasizes non-invasive methods, aiming to provide accessible and effective solutions for a wide range of health issues. The company's commitment to innovation is evident in its collaborative efforts with other health tech companies and its active role in advancing digital health technologies. The founders' involvement in Dopavision highlights their dedication to supporting and investing in innovative healthcare solutions. Their experience in the digital health sector positions Ababax Health as a key player in the development of digital therapeutics, contributing to the evolution of healthcare delivery through technology-driven interventions.

Investment Focus

• Innovative digital health solutions
• Non-invasive interventions
• Focus on mental and physical health
• Collaborative approach with multidisciplinary teams
• Scalable and accessible healthcare technologies
• Evidence-based efficacy
• Regulatory compliance
• Data privacy and security measures
• Sustainable business models
• Potential for global impact

Portfolio Companies